# XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

> **NCT05275374** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Xynomic Pharmaceuticals, Inc.** · enrollment: 221 (estimated)

## Conditions studied

- Cancer
- BRAF V600 Mutation
- Melanoma
- Colorectal Cancer
- Thyroid Cancer
- Nonsmall Cell Lung Cancer

## Interventions

- **DRUG:** XP-102
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT05275374
- **Lead sponsor:** Xynomic Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 221 (ESTIMATED)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05275374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05275374, "XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05275374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*